Interferon as adjunctive treatment for non-metastatic renal cell carcinoma

Br J Urol. 1994 Jul;74(1):11-4. doi: 10.1111/j.1464-410x.1994.tb16537.x.

Abstract

Objective: To investigate the effect of recombinant alpha 2b-interferon therapy on natural killer (NK) activity and antibody-dependent cell-mediated cytotoxicity (ADCC) in the peripheral blood in patients with renal cell carcinoma who had undergone radical nephrectomy.

Patients and methods: Between January 1988 and June 1989, 20 patients (14 men and six women, mean age 59 years, range 43-80) received interferon (IFN) therapy following radical nephrectomy for renal cell carcinoma. Thirteen patients had stage I disease, one had stage II and six had stage III; none had metastases.

Results: There was a significant increase in NK activity at 5 and 7 months after starting IFN therapy but there was no increase in ADCC.

Conclusions: Low doses of IFN administered long-term increased NK activity in patients with renal cell carcinoma. This finding should be helpful in designating protocols for randomized studies of post-operative IFN administration as adjuvant therapy.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibody-Dependent Cell Cytotoxicity / immunology
  • Carcinoma, Renal Cell / immunology
  • Carcinoma, Renal Cell / surgery
  • Carcinoma, Renal Cell / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Kidney Neoplasms / immunology
  • Kidney Neoplasms / surgery
  • Kidney Neoplasms / therapy*
  • Killer Cells, Natural / immunology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Nephrectomy
  • Recombinant Proteins

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins